Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
Authors:
- 17 October 2015
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 32 (11) , 937-945
Abstract
The aim of this study was to analyse the prevalence and predictors of drug combinations increasing bleeding risk among warfarin users with and without Alzheimer’s disease (AD). This retrospective observational study utilised data from the Finnish MEDALZ-2005 cohort. The MEDALZ-2005 study included all community-dwelling persons with a clinically verified diagnosis of AD at the end of 2005, and one comparison person without AD for each case. Data on drug use was collected from the Prescription Register. We included persons who were warfarin users during the study period 2006–2009. Drug combinations increasing bleeding risk with warfarin included selective serotonin reuptake inhibitors (SSRIs), non-steroidal anti-inflammatory agents (NSAIDs), other antithrombotic drugs and tramadol. Factors associated with combination use were investigated with logistic regression. During the follow-up, 3385 persons with AD and 4830 persons without AD used warfarin. Drug combinations increasing bleeding risk were more common in warfarin users with AD than without AD [35.9 and 30.5 %, respectively (p < 0.0001)]. The most common combination was SSRIs and warfarin, which was more common among persons with AD (23.8 %) than among persons without AD (10.9 %). NSAIDs and warfarin combination was more common among persons without AD. Combination use was associated with AD, female gender, younger age, diabetes mellitus, rheumatoid arthritis and asthma/chronic obstructive pulmonary disease (COPD). Use of drug combinations increasing bleeding risk was more common among warfarin users with AD. Special attention should be paid to minimise the duration of concomitant use and to find safer alternatives without increased bleeding risk.Keywords
This publication has 44 references indexed in Scilit:
- Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) studyClinical Epidemiology, 2013
- Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort studyBMJ Open, 2013
- Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patientsAmerican Heart Journal, 2011
- A systematic review of accidental injury from fire, wandering and medication self-administration errors for older adults with and without dementiaArchives of Gerontology and Geriatrics, 2011
- Prevalence of potentially hazardous drug interactions amongst Australian veteransBritish Journal of Clinical Pharmacology, 2010
- Validity of the Finnish Prescription Register for Measuring Psychotropic Drug Exposures among Elderly FinnsDrugs & Aging, 2010
- Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control studyBMJ, 2006
- Clinical Correlates and Drug Treatment of Residents With Stroke in Long-Term CareStroke, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984